Key strengths

Close relationships with patients and the people who care for them

Everything we do starts with a simple question: ‘How will this make a difference to the lives of people with severe diseases ?' Regular, personal contact with patients, as well as their carers and physicians, plays a vital role in helping us answer this question.

Cutting-edge research that combines biology and chemistry

Our expertise across large and small molecules enables us to
approach severe diseases from different angles. We are combining our leadership in antibody research and long-established expertise in chemistry to better understand and address the complex biological pathways and interconnections of these types of diseases. This is underpinned by unique technologies, such as UCB SLAM and A2Hit^TM.

Empowered, multidisciplinary and multinational teams

With more than 70 nationalities and numerous educational
and professional backgrounds, the diversity of our staff is one
of our greatest assets. To capitalise on the creative potential
of this diversity,  we have created an open, globally
networked environment so that our staff can share and cross
fertilise ideas.

World-class partners across the value chain

We recognise that the complexity of severe diseases is beyond
the expertise and resources of a single company. This is why we partner for strength across the value chain, from drug discovery and drug development to manufacturing and marketing.

A global player with a strong pipeline

With operations in more than 40 countries, UCB has global
reach. This includes an established presence in the world's major pharmaceutical markets: Germany, Italy, Japan, Spain, the U.K. and the U.S., as well as other significant international markets. In addition, our pipeline is strong especially in its late stage projects, and is focused on severe diseases of the central nervous system and immunology